HC Wainwright Has Negative Estimate for Oculis Q3 Earnings

Oculis Holding AG (NASDAQ:OCS) – HC Wainwright lowered their Q3 2026 EPS estimates for shares of Oculis in a note issued to investors on Monday, August 10th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.48) per share for the quarter, down from their prior forecast of ($0.47). HC Wainwright has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.15) per share. HC Wainwright also issued estimates for Oculis’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.75) EPS, Q1 2027 earnings at ($0.48) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.48) EPS, Q4 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.94) EPS.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The firm had revenue of $0.38 million for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%.

OCS has been the subject of a number of other reports. Stifel Nicolaus decreased their price objective on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 1st. Needham & Company LLC cut their target price on Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Finally, Robert W. Baird reduced their price objective on Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a report on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $38.33.

Oculis Trading Down 0.1%

NASDAQ:OCS opened at $12.75 on Wednesday. The company’s 50 day moving average price is $12.14 and its 200-day moving average price is $22.10. Oculis has a 52 week low of $10.52 and a 52 week high of $34.47. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. The stock has a market cap of $739.25 million, a price-to-earnings ratio of -7.33 and a beta of 0.51.

Hedge Funds Weigh In On Oculis

Several large investors have recently made changes to their positions in OCS. Gildi lifeyrissjodur purchased a new position in Oculis in the 4th quarter worth approximately $50,250,000. SR One Capital Management LP grew its holdings in Oculis by 98.8% during the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after buying an additional 318,522 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Oculis during the fourth quarter valued at approximately $9,862,000. Alyeska Investment Group L.P. lifted its holdings in shares of Oculis by 152.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after buying an additional 200,000 shares in the last quarter. Finally, Folketrygdfondet purchased a new position in shares of Oculis in the fourth quarter worth $3,651,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.